Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 27;14(3):629.
doi: 10.3390/cancers14030629.

Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma

Jesús García-Foncillas  1   2 , Antonio Tejera-Vaquerizo  3   4 , Onofre Sanmartín  5 , Federico Rojo  1 , Javier Mestre  6 , Salvador Martín  7 , Ignacio Azinovic  1 , Ricard Mesía  8
Affiliations
Review

Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma

Jesús García-Foncillas et al. Cancers (Basel). .

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, the incidence of which has risen over the last years. Although cSCC rarely metastasizes, early detection and treatment of primary tumours are critical to limit progression and local invasion. Several prognostic factors related to patients' clinicopathologic profile and tumour features have been identified as high-risk markers and included in the stratification scales, but their association with regional control or survival is uncertain. Therefore, decision-making on the diagnosis and management of cSCC should be made based on each individual patient's characteristics. Recent advances in non-invasive imaging techniques and molecular testing have enhanced clinical diagnostic accuracy. Surgical excision is the mainstay of local treatment, whereas radiotherapy (RT) is recommended for patients with inoperable disease or in specific circumstances. Novel systemic treatments including immunotherapies and targeted therapies have changed the therapeutic landscape for cSCC. The anti-PD-1 agent cemiplimab is currently the only FDA/EMA-approved first-line therapy for patients with locally advanced or metastatic cSCC who are not candidates for curative surgery or RT. Given the likelihood of recurrence and the increased risk of developing multiple cSCC, close follow-up should be performed during the first years of treatment and continued long-term surveillance is warranted.

Keywords: cutaneous squamous cell carcinoma; multidisciplinary management; prognosis; surgery; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

J. Garcia-Foncillas discloses consulting/advisory/honoraria speaker roles with Abbott, Amgen, Astellas, Astra Zeneca, Biocartis, Boehringer Ingelheim, BMS, Bayer, Celgene, Eisai, Foundation Medicine, GSK, Hospira, Janssen, Lilly, Merck Serono, MSD, Novartis, Pharmamar, Pfizer, Roche, Sanofi, Servier, Sysmex, and Tesaro. R. Mesía discloses consulting/advisory/honoraria speaker role with Amgen, BMS, Merck Serono, MSD, Roche, and Sanofi. O. Sanmartín discloses consulting/advisory/honoraria speaker role with Roche, ISDIN, and Sanofi. F. Rojo has received honorary for consultancy from Roche, BMS, MSD, Merck, Novartis, Pfizer, Astra Zeneca, Abbvie, Pierre Fabre, InCyte, and Bayer. J. Mestre discloses consulting/advisory/honoraria speaker roles with Lavigor, Roche, and Sanofi. A. Tejera has received honoraria for consultancy from Sanofi. S. Martín discloses consulting/advisory/honoraria speaker roles with MSD, Sanofi/Regeneron, BMS, Novartis, Roche, and Pierre-Fabre. I. Azinovic discloses no conflicts of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Histology and molecular pathology of photo-exposed skin, dysplasia, squamous carcinoma, and metastatic carcinoma.
Figure 2
Figure 2
Dermoscopy of cutaneous squamous cell carcinoma. (A) Wart-like tumour lesion on the dorsum of the nose; (B) dermoscopy with polarised light showing a predominantly vascular pattern with serpentine, hairpin and irregular vessels (arrows), central ulceration and blood staining; (C) crateriform keratinising tumour lesion; (D) polarised light dermoscopy with central whitish crust and presence of irregular and comma-shaped vessels (arrows) in the periphery; (E) crateriform tumour lesion; (F) polarised light dermoscopy showing white unstructured areas with irregular groups of white perifollicular circles, central vascular pattern with hairpin and irregular vessels (arrows).
Figure 3
Figure 3
Therapeutic algorithm for low- and high-risk SCC. cSCC, cutaneous squamous cell carcinoma; MMS, Mohs micrographic surgery; PNI, perineural invasion; RT, radiotherapy.
See this image and copyright information in PMC

References

    1. Karia P.S., Han J., Schmults C.D. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J. Am. Acad. Dermatol. 2013;68:957–966. doi: 10.1016/j.jaad.2012.11.037. - DOI - PubMed
    1. Flohil S.C., van der Leest R.J., Arends L.R., de Vries E., Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta-analysis. Eur. J. Cancer. 2013;49:2365–2375. doi: 10.1016/j.ejca.2013.03.010. - DOI - PubMed
    1. Tejera-Vaquerizo A., Descalzo-Gallego M.A., Otero-Rivas M.M., Posada-García C., Rodríguez-Pazos L., Pastushenko I., Marcos-Gragera R., García-Doval I. Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. Actas Dermosifiliogr. 2016;107:318–328. doi: 10.1016/j.ad.2015.12.008. - DOI - PubMed
    1. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B. 2001;63:8–18. doi: 10.1016/S1011-1344(01)00198-1. - DOI - PubMed
    1. Stern R.S. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: A 30-year prospective study. J. Am. Acad. Dermatol. 2012;66:553–562. doi: 10.1016/j.jaad.2011.04.004. - DOI - PubMed